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event (TEAE) rates comparable with controls. This analysis evaluated safety data from 14
trials (4 phase 2 and 10 phase 3, 8 to 104 weeks; n[ 5,234), in 2 pools according to control
(placebo/ezetimibe). Overall, 3,340 patients received alirocumab (4,029 patient-years’
exposure), 1,276 received placebo, and 618 received ezetimibe. Incidence of deaths, serious
TEAEs, discontinuations because of TEAEs, and overall TEAEs were similar between
alirocumab and control groups. Alirocumab was associated with a higher incidence of local
injection site reactions (7.4% vs 5.3% with placebo; 3.1% vs 2.3% with ezetimibe), pruritus
(1.3% vs 0.4% placebo; 0.9% vs 0.5% ezetimibe), and upper respiratory tract infection signs
and symptoms (2.1% vs 1.1% placebo; 1.3% vs 0.8% ezetimibe). Incidence of musculo-
skeletal, neurologic, neurocognitive, ophthalmologic, hepatic events, and TEAEs related to
diabetes/diabetes complications was similar between alirocumab and control groups. In a
prespeciﬁed analysis of phase 3 studies, adjudicated major adverse cardiovascular events
(coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, and un-
stable angina requiring hospitalization) occurred in 1.8% alirocumab versus 2.6% placebo
patients (hazard ratio 0.69, 95% conﬁdence interval 0.43 to 1.11) and 2.8% alirocumab
versus 1.5% ezetimibe patients (hazard ratio 1.4, 95% conﬁdence interval 0.65 to 3.02). In
conclusion, pooled safety data from 14 trials demonstrate that alirocumab is generally well
tolerated with a favorable safety proﬁle.  2016 The Author(s). Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2016;118:1805e1811)Alirocumab, a monoclonal antibody to proprotein con-
vertase subtilisin/kexin type 9 (PCSK9), was approved by
the US Food and Drug Administration and the European
Medicines Agency in 2015 for the treatment of adults with
hypercholesterolemia who require additional lowering of
low-density lipoprotein cholesterol (LDL-C). Alirocumab
has been studied in phase 2 and 3 clinical trials with double-
blind treatment periods of 8 to 104 weeks.1e13 The phase 3
(ODYSSEY) trials mainly recruited patients at high
atherosclerotic cardiovascular disease risk, including those
with heterozygous familial hypercholesterolemia, who had
elevated LDL-C levels despite receiving maximally toler-
ated statin. In individual trials, alirocumab signiﬁcantly
reduced levels of LDL-C versus controls, and overall rates
of treatment-emergent adverse events (TEAEs) and dis-
continuations were similar between alirocumab and controle of Medicine, Houston, Texas; bLouisville Metabolic
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0.1016/j.amjcard.2016.08.072groups. The alirocumab clinical trial program was designed
to provide extensive safety information. To better assess
safety of alirocumab, this report presents pooled safety data
from >5,000 patients who participated in 14 randomized,
double-blind, controlled phase 2 and 3 trials.
Methods
Data from 14 trials (4 phase 2 and 10 phase 3) of 8 to
104 weeks’ duration were analyzed (Figure 1).1e13 All
study protocols were approved by the appropriate institu-
tional review board, and all patients provided informed,
written consent. Further details on the trials are given in the
Supplementary Material.
This analysis focuses on TEAEs, deﬁned as events
occurring from the ﬁrst dose of study treatment to the last
dose (plus 70 days to account for the prolonged effect of
alirocumab). Adverse events (AEs) of special interest cate-
gories were deﬁned based on potential theoretical risks for
the new drug class and included local injection site
reactions, general allergic, neurologic, neurocognitive,
hepatic, ophthalmologic, diabetes related, and musculo-
skeletal events (Supplementary Table 1). Cardiovascular
events were adjudicated in the phase 3 trials. Laboratory
values were also assessed. Statistical analyses compared
incidence of AEs of interest and commonly occurring (not
prespeciﬁed) AEs between alirocumab and either placebo or
ezetimibe in pools according to control used. Further details
on methods are given in the Supplementary Material.ccess article
4.0/).
www.ajconline.org
Figure 1. Numbers of patients who received alirocumab, placebo, or ezetimibe from each study who were included in the pooled safety analysis. This analysis
includes safety data from 4 phase 2 and 10 phase 2 trials. The ﬁgure indicates the trial names, patient population, background therapy, duration of double-blind
treatment in weeks, and number of patients who received alirocumab, placebo, or ezetimibe and were included in the analysis. “*,” Fixed doses of atorvastatin
20 or 40 mg were used in OPTIONS I and rosuvastatin 10 or 20 mg in OPTIONS II. Study references (clinicaltrials.gov identiﬁers): DFI111565
(NCT01288443),2 DFI11566 (NCT01288469),1 CL-1003 (NCT01266876),3 DFI12361 (NCT01812707),13 LONG TERM (NCT01507831),8 HIGH FH
(NCT01617655),5 COMBO I (NCT01644175),7 FH I (NCT01623115) þ FH II (NCT01709500),9 COMBO II (NCT01644188),6 OPTIONS I
(NCT01730040),10 OPTIONS II (NCT01730053),12 MONO (NCT01644474),4 and ALTERNATIVE (NCT01709513).11 ALI 150 ¼ alirocumab 150 mg
Q2W; ALI 75 ¼ alirocumab 75 mg Q2W; ALI 75/150 ¼ alirocumab 75 mg Q2W with dose increase to 150 mg Q2W at week 12 depending on week 8 LDL-C
level; CV ¼ cardiovascular; EZE ¼ ezetimibe; HeFH ¼ heterozygous familial hypercholesterolemia; LDL-C ¼ low-density lipoprotein cholesterol;
LLT ¼ lipid-lowering therapy; non-FH ¼ non-familial hypercholesterolemia; PBO ¼ placebo; Q2W ¼ every 2 weeks.
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Table 1
Baseline characteristics
Variable Placebo-controlled pool Ezetimibe-controlled pool
Alirocumab
(n ¼ 2,476)
Placebo
(n ¼ 1,276)
Alirocumab
(n ¼ 864)
Ezetimibe
(n ¼ 618)
Age (years, meanSD) 58.611.6 58.511.3 61.99.4 62.19.5
Men 1,482 (59.9%) 763 (59.8%) 581 (67.2%) 387(62.6%)
White 2,232 (90.1%) 1,136 (89.0%) 745 (86.2%) 546 (88.3%)
Black 101 (4.1%) 57 (4.5%) 50 (5.8%) 37 (6.0%)
Asian 75 (3.0%) 37 (2.9%) 41 (4.7%) 27 (4.4%)
Hispanic/Latino 153 (6.3%) 77 (6.2%) 50 (5.8%) 41 (6.7%)
BMI (kg/m2, meanSD) 29.95.6 30.25.6 30.26.0 30.05.7
Calculated LDL-C (mg/dL, meanSD) 126.645.3 126.643.8 123.251.5 125.556.9
Statin therapy* 2,316 (>99.9%) 1.173 (>99.9%) 688 (79.6%) 453 (73.3%)
Maximally tolerated statin† 2,318 (100%) 1,174 (100%) 479 (55.4%) 241 (39.0%)
High-dose statinz 1,325 (57.2%) 682 (58.1%) 430 (49.8%) 264 (42.7%)
Non-statin LLTx 823 (35.5%) 430 (36.6%) 93 (10.8%) 89 (14.4%)
Type 2 diabetes* 683 (29.5%) 344 (29.3%) 280 (32.4%) 190 (30.7%)
HeFH{ 853 (36.5%) 433 (36.4%) 40 (4.6%) 43 (7.0%)
ASCVD* 1,611 (69.5%) 834 (71.0%) 651 (75.3%) 409 (66.2%)
CHD 1,450 (62.6%) 766 (65.2%) 611 (70.7%) 388 (62.8%)
ACS 976 (42.1%) 528 (45.0%) 433 (50.1%) 266 (43.0%)
Peripheral artery disease 97 (4.2%) 56 (4.8%) 33 (3.8%) 18 (2.9%)
Ischemic stroke 199 (8.6%) 86 (7.3%) 59 (6.8%) 36 (5.8%)
ACS ¼ acute coronary syndrome; ASCVD ¼ atherosclerotic cardiovascular disease; BMI ¼ body mass index; CHD ¼ coronary heart disease;
HeFH ¼ heterozygous familial hypercholesterolemia; LLT ¼ lipid-lowering therapy; SD ¼ standard deviation.
* Data for placebo-controlled pools from phase 3 studies only (n ¼ 2,318 alirocumab, n ¼ 1,174 placebo).
† Patients in placebo-controlled phase 3 studies and COMBO II were receiving maximally tolerated statin, see Figure 1.
z Atorvastatin 40 or 80 mg, rosuvastatin 20 or 40 mg, or simvastatin 80 mg.
x Excluding nutraceuticals.
{ HeFH data for placebo-controlled pool from phase 3 placebo-controlled studies and phase 2 study CL-1003 (n ¼ 2,334 alirocumab, n ¼ 1,189 placebo).
Data from pool of phase 2 and 3 studies.
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Safety data were available for 3,340 patients treated with
alirocumab (representing 4,029 patient-years of alirocumab
exposure), 1,276 treated with placebo, and 618 treated with
ezetimibe (Figure 1). Baseline characteristics were similar
for alirocumab and control groups (Table 1). All patients in
phase 3 placebo-controlled studies and most in the
ezetimibe-controlled studies were receiving maximally
tolerated statin (Table 1) as per the study designs (Figure 1).
Baseline characteristics and LDL-C efﬁcacy data from the
individual trials are listed in Supplementary Tables 2 and 3.
Overall rates of TEAEs, serious AEs, discontinuations,
and deaths were similar between alirocumab and control
groups in both pools (Table 2). Details of deaths are given in
Supplementary Table 4.
Local injection site reactions were reported by a signiﬁ-
cantly higher proportion of alirocumab-treated patients
compared with placebo (7.4% vs 5.3%; hazard ratio [HR]
1.47, 95% conﬁdence interval [CI] 1.11 to 1.95) and by a
nonsigniﬁcantly higher proportion of alirocumab-treated
patients versus ezetimibe (3.1% vs 2.3%; HR 1.49, 95%
CI 0.78 to 2.86; Table 3). Few patients withdrew from the
trials because of local injection site reactions (Table 3), and
no serious events were reported. Most local injection site
reactions were graded as mild in severity and transient. Two
events were graded as severe: 1 in an alirocumab-treated
patient that resolved in 1 day without treatment and didnot result in treatment discontinuation and 1 in a patient
allocated to ezetimibe who reported a severe reaction from
the placebo injection that required treatment and resulted in
treatment discontinuation.
General allergic events were overall reported at similar
rates with alirocumab versus control in both pools and few
were reported as being serious (Table 3). Of the speciﬁc
events that form this category (Supplementary Table 5), a
signiﬁcantly higher incidence of pruritus was observed with
alirocumab versus placebo (1.3% vs 0.4%; HR 3.15, 95% CI
1.22 to 8.09); pruritus was reported in 0.9% alirocumab
versus 0.5% ezetimibe patients (HR 1.86, 95% CI 0.49 to
7.11). Other rarer, sporadic allergic AEs occurred, including
hypersensitivity, eczema nummular, urticaria, and hyper-
sensitivity vasculitis.
Neurologic events occurred at similar rates in alir-
ocumab and control groups and few led to treatment
discontinuation (Table 3). Serious neurologic events
reported with alirocumab were single occurrences, without
evidence of a common underlying pathogenic mechanism.
Incidence of neurocognitive events was low and similar
between alirocumab and control groups (Table 3). The
most common neurocognitive events were memory loss
and amnesia (both 0.5% of patients; Supplementary
Table 5). Ophthalmologic events occurred at similar
rates in the alirocumab groups compared with controls
(Table 2).
Table 2
Overall frequencies of adverse events and events in 5% of patients
Variable Placebo-controlled pool Ezetimibe-controlled pool
Alirocumab
(n ¼ 2,476)
Placebo
(n ¼ 1,276)
Alirocumab
(n ¼ 864)
Ezetimibe
(n ¼ 618)
Any TEAE 1,942 (78.4%) 1,004 (78.7%) 657 (76.0%) 457 (73.9%)
SAE 387 (15.6%) 205 (16.1%) 147 (17.0%) 86 (13.9%)
Leading to treatment discontinuation 148 (6.0%) 71 (5.6%) 84 (9.7%) 66 (10.7%)
Leading to death 16 (0.6%) 13 (1.0%) 6 (0.7%) 9 (1.5%)
TEAEs in 5% of patients
Nasopharyngitis 301 (12.2%) 147 (11.5%) 52 (6.0%) 41 (6.6%)
Upper respiratory tract infection 165 (6.7%) 97 (7.6%) 62 (7.2%) 40 (6.5%)
Inﬂuenza 147 (5.9%) 63 (4.9%) 37 (4.3%) 23 (3.7%)
Urinary tract infection 129 (5.2%) 65 (5.1%) 21 (2.4%) 25 (4.0%)
Back pain 126 (5.1%) 71 (5.6%) 33 (3.8%) 26 (4.2%)
Arthralgia 119 (4.8%) 79 (6.2%) 42 (4.9%) 26 (4.2%)
Myalgia 112 (4.5%) 47 (3.7%) 62 (7.2%) 48 (7.8%)
Diarrhea 128 (5.2%) 61 (4.8%) 30 (3.5%) 21 (3.4%)
Headache 126 (5.1%) 67 (5.3%) 43 (5.0%) 24 (3.9%)
Accidental overdose 35 (1.4%) 17 (1.3%) 54 (6.3%) 24 (3.9%)
SAE ¼ serious adverse event; TEAE ¼ treatment-emergent adverse event.
Data pooled from phase 2 and 3 studies.
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aminotransferase (ALT) elevations, was similar between
alirocumab versus controls (Table 3). Single elevations of
ALT and aspartate aminotransferase were observed in
similar frequencies in alirocumab and control groups
(Supplementary Table 6). There were 4 cases overall (2 with
alirocumab and 2 with placebo) of combined elevations in
ALT and bilirubin levels falling into Hy’s law range
(3 times upper limit of normal [ULN] and 2 times ULN,
respectively); however, all these cases had alternative
etiologies (e.g., hepatitis A or pre-existing liver disease). No
cases of hemolytic anemia were reported. Levels of hemo-
globin were similar between alirocumab and control groups
and did not change over the course of any of the studies.
There was no difference in incidence of musculoskeletal
events between alirocumab and placebo, and fewer
alirocumab-treated patients had musculoskeletal events
overall versus ezetimibe in the ALTERNATIVE study
(Table 3). There were no signiﬁcant differences between
groups in rates of speciﬁc musculoskeletal events, including
myalgia (Supplementary Table 5). Most musculoskeletal
events were mild to moderate in severity, and severity was
comparable between treatment groups. Elevated creatine
kinase >3 or >10 times ULN was reported in a similar
proportion of patients in alirocumab and control groups
(Supplementary Table 6).
AEs related to diabetes were infrequent, with no differ-
ence between alirocumab and control groups (Table 3).
There were no differences in the change in fasting plasma
glucose and glycated hemoglobin (HbA1c) over time be-
tween alirocumab and control groups, regardless of diabetes
status at baseline (Supplementary Figures 1 and 2 online).
Major adverse cardiovascular events occurred in 1.8%
alirocumab versus 2.6% placebo patients (HR 0.69, 95% CI
0.43 to 1.11) and in 2.8% alirocumab versus 1.5% ezetimibe
patients (HR 1.40, 95% CI 0.65 to 3.02). Further details on
cardiovascular events are given in Supplementary Table 7.Aside from local injection site reactions and pruritus,
rates of other AEs were similar between alirocumab and
control groups, including gastrointestinal AEs, such as
diarrhea, nausea, and constipation (Table 2; Supplementary
Table 8). An exception was the Medical Dictionary of
Regulatory Activities higher level term “upper respiratory
tract infections signs and symptoms” (including mainly
oropharyngeal pain, rhinorrhea, and sneezing), which was
reported at a statistically higher rate with alirocumab versus
placebo (2.1% vs 1.1%; HR 1.87, 95% CI 1.04 to 3.38); the
difference between alirocumab versus ezetimibe was not
signiﬁcant (1.3% vs 0.8%; HR 1.44, 95% CI 0.49 to 4.20;
further details given in Supplementary Table 9). Among
alirocumab-treated patients, there was no increased inci-
dence of this event category for patients who had LDL-C
values <25 mg/dl (1.3%) compared with those who did
not have such LDL-C values (1.8%).
Discussion
This is the largest safety analysis of alirocumab in terms
of patient numbers (3,340 treated with alirocumab) and
exposure (4,029 patient-years). Most patients were observed
for 52 weeks in double-blind studies, with 64.4%
observed for up to 76 weeks. Overall rates of TEAEs, SAEs,
premature discontinuations, and deaths were similar be-
tween alirocumab treatment and control groups (placebo and
ezetimibe).
Rates of local injection site reactions occurred at a higher
rate with alirocumab versus controls; most injection site
reactions were transient, few led to discontinuation, and
most were mild in severity. Local injection site reactions
could represent local intolerability because of the device or
the drug, the viscosity, volume, or other aspects of which
may have contributed to symptoms, such as pain, stinging,
and redness. Furthermore, as patients with persistently
positive anti-drug antibodies have been shown to experience
Table 3
Adverse events of interest*
Variable Placebo-controlled pool Ezetimibe-controlled pool
Alirocumab
(n ¼ 2,476)
Placebo
(n ¼ 1,276)
Alirocumab
(n ¼ 864)
Ezetimibe
(n ¼ 618)
Local injection site reactions 183 (7.4%) 67 (5.3%) 27 (3.1%) 14 (2.3%)
Rate per 100 patient-years† 5.8 4.1 2.5 2.2
HR vs control (95% CI) 1.47 (1.11 to 1.95) 1.49 (0.78 to 2.86)
Leading to discontinuation 5 (0.2) 4 (0.3) 3 (0.3) 2 (0.3)
General allergic events 237 (9.6%) 105 (8.2%) 67 (7.8%) 38 (6.1%)
Rate per 100 patient-years† 7.5 6.5 6.3 6.1
HR vs control (95% CI) 1.15 (0.92 to 1.45) 1.23 (0.82 to 1.85)
SAEs 12 (0.5%) 5 (0.4%) 2 (0.2%) 2 (0.3%)
Leading to discontinuation 15 (0.6%) 3 (0.2%) 7 (0.8%) 2 (0.3%)
Neurologic events 99 (4.0%) 52 (4.1%) 35 (4.1%) 19 (3.1%)
Rate per 100 patient-years† 3.0 3.1 3.2 3.0
HR vs control (95% CI) 0.98 (0.70 to 1.37) 1.27 (0.72 to 2.24)
SAEs 6 (0.2%) 3 (0.2%) 4 (0.5%) 2 (0.3%)
Leading to discontinuation 6 (0.2%) 2 (0.2%) 4 (0.5%) 3 (0.5%)
Neurocognitive disorders 22 (0.9%) 9 (0.7%) 10 (1.2%) 8 (1.3%)
Rate per 100 patient-years† 0.7 0.5 0.9 1.2
HR vs control (95% CI) 1.24 (0.57 to 2.68) 0.81 (0.32 to 2.08)
SAEs 3 (0.1%) 2 (0.2%) 1 (0.1%) 1 (0.2%)
Leading to discontinuation 0 2 (0.2%) 1 (0.1%) 3 (0.5%)
Ophthalmological events 54 (2.2%) 20 (1.6%) 10 (1.2%) 5 (0.8%)
HR vs control (95% CI) 1.37 (0.82 to 2.29) 1.11 (0.38 to 3.27)
Hepatic disorders 72 (2.9%) 29 (2.3%) 23 (2.7%) 16 (2.6%)
HR vs control (95% CI) 1.28 (0.83 to 1.97) 0.84 (0.44 to 1.59)
Musculoskeletal eventsz 415 (16.8%) 215 (16.8%) 41 (32.5%) 52 (41.9%)
HR vs control (95% CI) 0.99 (0.84 to 1.17) 0.69 (0.46 to 1.04)
Patients without diabetes at baselinex n ¼ 1,761 n ¼ 908 n ¼ 581 n ¼ 427
Diabetes mellitus or diabetic complications AEs 27 (1.5%) 22 (2.4%) 19 (3.3%) 11 (2.6%)
HR vs control (95% CI) 0.61 (0.35 to 1.08) 0.91 (0.43 to 1.93)
Patients with diabetes at baselinex n ¼ 715 n ¼ 368 n ¼ 283 n ¼ 191
Diabetes mellitus or diabetic complications AEs 85 (11.9%) 40 (10.9%) 21 (7.4%) 18 (9.4%)
HR vs control (95% CI) 1.07 (0.73 to 1.55) 0.72 (0.38 to 1.35)
CI ¼ conﬁdence interval; HR ¼ hazard ratio; SAE ¼ serious adverse event; TEAE ¼ treatment-emergent adverse event.
* Pool of phase 2 and 3 studies. Certain categories of AEs were assessed based on identiﬁed, potential, and theoretical risks for the new drug class collected
during the clinical trial program. See further explanation in the online supplement text and Supplementary Table 1. Further details in results including speciﬁc
events are shown in Supplementary Table 5.
† Number of patients with an event divided by total patient-years.
z Ezetimibe-controlled pool data are for ALTERNATIVE only (n ¼ 126 alirocumab, 124 ezetimibe), due to the high rate of events in this study of patients
with documented statin intolerance that would otherwise skew results if pooled with the other ezetimibe-controlled trials.
x Baseline diabetes deﬁned based on medical history.
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patients without such antibodies,14 an immune-based
response is possible; however, the precise mechanism is
unknown. Similarly, the precise mechanism for the
increased rate of pruritus with alirocumab is unknown.
Most patients were receiving concomitant statins at
maximally tolerated dose. Safety events associated with
statin treatment include muscle symptoms and increased
incidence of diabetes.15e17 Importantly, the addition of
alirocumab treatment was not associated with any increase
neither in musculoskeletal events (including myalgia or
clinically meaningful changes in creatine kinase levels) nor
in hepatic disorders, including single elevations in ALT, and
no cases of conﬁrmed Hy’s law were observed. Incidence of
AEs related to diabetes was similar between alirocumab and
controls (including no clinically meaningful differences
between mean HbA1c and fasting plasma glucose levelsbetween groups). Furthermore, alirocumab does not increase
incidence of new-onset diabetes based on phase 3 data.18
Although our analysis did not ﬁnd any neurocognitive
event differences between alirocumab and placebo/ezeti-
mibe, a network meta-analysis of phase 2 and 3 trials with
alirocumab and evolocumab did ﬁnd the incidence of neu-
rocognitive events to be increased (odds ratio 2.34, 95% CI
1.11 to 4.93, p ¼ 0.02), primarily because of their inclusion
of the 2 large, long-term trials of both drugs.8,19,20 However,
this meta-analysis only included 2 alirocumab phase 3
studies (LONG TERM and COMBO I), whereas our pooled
analysis includes 14 trials. Another recent meta-analysis of
PCSK9 antibody trials did not provide any neurocognitive
AE data.21 Dedicated neurocognitive trials are planned to
address this issue further.
Although the rate of the higher level term category
“upper respiratory tract infection signs and symptoms” was
1810 The American Journal of Cardiology (www.ajconline.org)signiﬁcantly greater with alirocumab (2.1%) versus placebo
(1.1%), this was considered to be a chance ﬁnding. We have
no mechanistic basis for an increase in this AE category
with alirocumab, and this ﬁnding was not related to low
levels of LDL-C.
This analysis reports the largest and longest safety data
for a PCSK9 monoclonal antibody available to date. How-
ever, it was limited by the number of patients and the overall
duration of the studies for examination of rare events (e.g.,
only 32 neurocognitive events were reported in the alir-
ocumab group). Furthermore, none of the data included in
this analysis were derived from a prospective clinical trial
designed to determine the effect of alirocumab on cardio-
vascular events and safety. The ongoing 18,000-patient
ODYSSEY OUTCOMES trial will provide sufﬁcient sta-
tistical power to adequately determine the effect of alir-
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